A Lenalidomide-Inducible Suicide Switch for Gene- and Cell-Based Therapy
Genetically modified immune effector cells, including chimeric antigen receptor (CAR) T cells, have emerged as transformative anti-cancer agents. However, these autonomous, living therapies are limited by difficult-to-control hyperactivation toxicities. To achieve their full potential as therapies for a broader range of diseases, CAR T cells must target novel antigens and integrate further…
We haven't written up this one. bioRxiv has the full story — the link below goes straight to it.
